17(R)-Resolvin D1 (17(R)-RvD1) is an aspirin-triggered epimer of RvD1 that reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with equipotency to RvD1 (EC50 = ~30 nM). 17(R)-RvD1 exhibits a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with maximal inhibition of ~35% at a 100 ng dose. In contrast to RvD1, the aspirin-triggered form resists rapid inactivation by eicosanoid oxidoreductases. 17(R)-RvD1 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
17(R)-Resolvin D1 methyl ester is the methyl ester of Resolvin D1 (RvD1) (HY-125527) induced by Aspirin (HY-14654) with the 17R epimer (AT-RvD1). RvD is a regulator of transendothelial migration of human polymorphonuclear leukocytes and an anti-inflammatory agent. The 17R-trihydroxy-4Z of RvD1 also blocks transendothelial migration of human neutrophils (EC50 approximately 30 nM). AT-RvD1 is an effective form that protects against the rapid inactivation of Resolvin D1[1].